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Resistance to anti-estrogen therapy is a major clinical concern in treatment of breast cancer. Estro-
gen-independent phosphorylation of estrogen receptor a, speciﬁcally on Ser167, is one of the con-
tributing causes to development of resistance, and a prognostic marker for the disease. Here, we
dissect the signaling pathways responsible for Ser167 phosphorylation. We report that the mTOR/
S6K1 and MAPK/RSK contribute non-overlapping inputs into ERa activation via Ser167 phosphory-
lation. This cooperation may be targeted in breast cancer treatment by a combination of mTOR and
MAPK inhibitors.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The mammalian target of rapamycin (mTOR) is a conserved pro-
tein kinase that is a key regulator of cell growth and proliferation
in response to nutrient availability and growth stimuli. Rapamycin
is a naturally-derived inhibitor of mTOR, and an inhibitor of cell
proliferation, as manifested by its potent immunosuppressive
properties and activity against solid tumors [1]. Recent work led
to the realization that rapamycin does not perturb all mTOR func-
tions because mTOR exists in two complexes in eukaryotic cells,
mTOR complexes 1 and 2 (mTORC1 and 2). mTORC1 and mTORC2
consist of distinct sets of proteins and perform non-redundant
functions [2]. This work focuses on the rapamycin-sensitive
mTORC1 signaling.
In response to a variety of stimuli, including mitogens and hor-
mones, the mitogen-activated protein kinase (MAPK) and mTORC1
pathways regulate important cellular processes such as cell
growth, proliferation, and survival [3,4]. There exists an extensivechemical Societies. Published by E
gen-activated protein kinase;
target of rapamycin; ERa,
cetate; PKC, protein kinase C
f Biology, Stern College for
USA. Fax: +1 212 340 7883.cross-talk between MAPK and mTORC1 signaling in cells. Corre-
spondingly, the effectors of these pathways, the p90 ribosomal
S6 kinase (RSK) and the p70 S6 kinase 1 (S6K1) have been shown
to converge on a common set of targets, most notably in control
of protein translation [5–7]. In this study, we identify estrogen
receptor a (ERa) as a recipient of coordinated phosphorylation in-
puts from the MAPK and mTORC1 pathways.
ERa mediates the proliferative effects of estrogen and repre-
sents an important clinical target in treatment of breast cancer.
Tamoxifen is an anti-estrogen that has become the standard agent
for the treatment of ER-positive breast cancer, where it acts as an
antagonist. However, resistance to tamoxifen, and other endocrine
or anti-estrogen therapies develops in many cases [8,9]. One mech-
anism by which resistance develops is through phosphorylation of
ERa, allowing it to act in estrogen-independent manner. As illus-
trated in Fig. 1, the N-terminal estrogen-independent activation
AF-1 domain of ERa is responsible for ligand-independent transac-
tivation function of ERa. ERa phosphorylation within the AF-1 do-
main occurs on residues Ser104/106, Ser118, and Ser167. Ser104/
106 phosphorylation is regulated by cdk [10], and Ser118
phosphorylation is regulated by MAPK [11,12], although it has
been suggested that MAPK controls this event indirectly [13]. Phos-
phorylation of Ser167 has been previously attributed to Akt and
RSK [14,15], while we have demonstrated that S6K1 is the physio-
logical ERa Ser167 kinase and it phosphorylates this site inlsevier B.V. All rights reserved.
Fig. 1. Domain architecture of estrogen receptor a (ERa), and location of phosphorylation sites within the AF-1 domain.
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lation correlates with resistance to tamoxifen [14] and is a prog-
nostic marker for disease progression and survival [17]. Thus, the
identity of the kinase(s) responsible for this phosphorylation event
has important clinical consequences.
RSK and S6K1 recognize identical consensus phosphorylation
sequence RxRxxS/T, where x is any amino acid, and they share
common phosphorylation targets [5,6]. ERa contains a phosphory-
lation motif RERLAS167 (Fig. 1), and both kinases have been shown
to directly phosphorylate this site in in vitro kinase assays [15,16].
Because of the different kinetics of mitogen-mediated activation of
the mTORC1/S6K1 and MAPK/RSK signaling pathways, it is possible
that RSK may play a physiological role in phosphorylation of ERa.
Therefore, we set out to determine the relative contributions of
the MAPK/RSK and mTORC1/S6K1 signaling pathways to phos-
phorylation and activation of ERa. In this study, we demonstrate
that in response to activating stimuli S6K1 and RSK phosphorylate
ERa, allowing for coordinate regulation of ERa activation.
2. Materials and methods
2.1. Reporter and expression vectors
pGL2-3xERE-TATA-luc was kindly provided by Donald P.
McDonnell (Duke University, Durham, NC), and pIS2 renilla lucifer-
ase reporter was kindly provided by David Bartel (MIT, Cambridge,
MA).
2.2. Cell culture
MCF7 cells were maintained in Dulbecco’s modiﬁed Eagle med-
ium (DMEM) containing 10% fetal bovine serum (FBS).
2.3. RNAi against RSK1/2
For the siRNA studies, double-stranded RNAs for RSK1 and RSK2
were a kind gift from John Blenis (Harvard Medical School, Boston,
MA). MCF7 cells were transfected using Lipofectamine2000 (Invit-
rogen) according to the manufacturer’s recommendations. After
24 h post-transfection, cells were deprived of serum overnight,
treated with agents as indicated in the ﬁgure legend.
2.4. Reporter gene assays
For luciferase reporter assays, cells were transfected using Lipo-
fectamine2000 (Invitrogen) using the manufacturer’s protocol with
plasmids encoding for ﬁreﬂy luciferase under control of three ERE,
and control renilla luciferase. At 24 h post-transfection, rapamycin
(20 ng/mL) and/or U0126 (Biomol, 10 lM) were added where indi-
cated. At 48 h post-transfection, cells were harvested using 1 Pas-
sive Lysis Buffer (Promega), and relative luciferase activity wasmeasured using the Dual Luciferase Reporter Assay System and
Glomax 20/20 luminometer (Promega).
2.5. Immunoblots
Cells were lysed using 1 Passive Lysis Buffer (Promega).
Whole-cell lysates (10% of total cell extract) were resolved by so-
dium dodecyl sulfate (SDS)–polyacrylamide gel electrophoresis
(PAGE) (10%). Proteins were transferred to a nitrocellulose
membrane (Schleicher and Schuell) and blotted with the indicated
antibodies. Anti-phospho-ERK1/2 antibodies were from Sigma.
Anti-phospho-S6K1 Thr389, anti-phospho-S6 Ser235/236, anti-
phospho-S6 Ser240/244, and anti-phospho-ER Ser167 antibodies
were purchased from Cell Signaling Technology. Anti-ER antibodies
were from Santa Cruz Biotechnology. Anti RSK1 and RSK2 antibod-
ies were from Zymed. For immunoblotting, anti-rabbit, anti-
mouse, and anti-goat horseradish peroxidase (HRP)-conjugated
antibodies were purchased from Amersham, Chemicon, and Santa
Cruz Biotechnology, respectively. Immunoblots were developed
using enhanced chemiluminescence reagents (Pierce) and Chemi-
doc XRS imager with Quantity One software (Bio-Rad).
3. Results and discussion
3.1. Rapamycin-resistant ERa Ser167 phosphorylation in cells growing
in serum-supplemented media
To evaluate the relative contribution of the MAPK and S6K1 sig-
naling pathways to phosphorylation of ERa Ser167, MCF7 cells
growing in 10% FBS were treated with the mTORC1 inhibitor rapa-
mycin and MEK inhibitor U0126. As shown in Fig. 2A, treatment
with rapamycin severely reduced Ser167 phosphorylation, how-
ever, some rapamycin-insensitive phosphorylation remained.
While treatment with U0126 only slightly reduced phosphoryla-
tion levels, treatment with a combination of rapamycin and
U0126 resulted in complete inhibition of Ser167 phosphorylation.
This indicated that there exists a rapamycin-insensitive MAPK in-
put into Ser167 phosphorylation.
3.2. Acute mitogenic stimulation of ERa Ser167 phosphorylation
reveals MAPK and mTORC1/S6K1 inputs
To dissect the signaling inputs into ERa Ser167 phosphoryla-
tion, we interrogated the sensitivity of Ser167 phosphorylation to
acute mitogenic stimulation. We deprived MCF7 cells of serum,
and acutely stimulated them insulin, which preferentially activates
the mTORC1/S6K1 pathway, or the phorbol ester phorbol 12-myr-
istate 13-acetate (PMA), which activates both the mTORC1/S6K1
and MAPK pathways. We also investigated the effect of rapamycin
and U0126 inhibitors on insulin- and PMA-stimulated ERa Ser167
phosphorylation. As shown in Fig. 2B, 30 min treatment with insu-
Fig. 2. Rapamycin-resistant ERa Ser167 phosphorylation is mediated by mitogen-
activated protein kinase (MAPK)/p90 ribosomal S6 kinase (RSK) signaling. (A) Cells
were grown in media containing 10% FBS, supplemented with 10 lM U0126 and/or
20 ng/mL rapamycin overnight, where indicated, and proteins were analyzed by
immunoblots. (B) Cells were deprived of serum for 24 h, then pre-treated with
20 ng/mL rapamycin for 30 min and/or 10 lM U0126 for 2 h, and stimulated with
100 nM insulin or 100 ng/mL phorbol 12-myristate 13-acetate (PMA) for 30 min.
Proteins were analyzed by immunoblots. (C) RNAi suppressing RSK1/2 expression
reduces ERa Ser167 phosphorylation. Cells were transfected with siRNA targeting
RSK1/2 or mock oligonucleotides. At 24 h post-transfection, cells were deprived of
serum for additional 24 h. Cells were pre-treated with 20 ng/mL rapamycin for
30 min, and then stimulated with 100 nM insulin or 100 ng/mL PMA for 30 min.
Proteins were immunoblotted with the indicated antibodies.
Fig. 3. Temporal regulation of ERa Ser167 phosphorylation by MAPK/RSK and p70
S6 kinase 1 (S6K1). Cells were deprived of serum for 24 h, and stimulated with
100 nM insulin or 100 ng/mL PMA, as indicated. Proteins were analyzed by
imunoblots.
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alone did not appear to inhibit ERa Ser167 phosphorylation, how-
ever, we observed a residual rapamycin-insensitive phosphoryla-
tion of ERa Ser167 phosphorylation. Accordingly, a combination
of rapamycin and U0126 resulted in a greater inhibition of
Ser167 phosphorylation than rapamycin alone. These ﬁndings indi-
cated that S6K1 is the major contributor to Ser167 phosphorylation
following insulin stimulation, while the MAPK pathway has a min-
or role. We next looked at the effect of PMA stimulation on Ser167
phosphorylation. Similar to insulin treatment, 30 min stimulation
with PMA resulted in rapamycin-sensitive Ser167 phosphoryla-
tion. However, PMA-induced Ser167 phosphorylation was also par-
tially U0126-sensitive. Treatment with a combination of
rapamycin and U0126 abolished ERa Ser167 phosphorylation.
Therefore, while the mTORC1/S6K1 pathway is the major signaling
pathway phosphorylating Ser167, in response to activating stimuli,
the MAPK pathway also contributes to this phosphorylation.3.3. RNAi of RSK1/2 suppresses ERa Ser167 phosphorylation
Since PMA stimulation leads to activation of RSK, we inquired
whether RSK may mediate rapamycin-insensitive Ser167 phos-
phorylation. To that end, we reduced expression of RSK isoforms
RSK1 and RSK2 in MCF7 cells by means of siRNA, and acutely stim-
ulated these cells with insulin or PMA, with or without rapamycin.
As shown in Fig. 2C, while RNAi against RSK1/2 did not have an ef-
fect on insulin-mediated ERa Ser167 phosphorylation, PMA-in-
duced phosphorylation was reduced in cells with RSK1/2
knockdown. Thus, RSK mediates rapamycin-insensitive ERa
Ser167 phosphorylation in response to PMA stimulation.
3.4. Temporal regulation of ERa Ser167 phosphorylation by MAPK/RSK
and S6K1
The S6K1 and MAPK pathways exhibit differential patterns of
temporal activation. We compared the timing of RSK and S6K1
contributions to Ser167 phosphorylation. As shown in Fig. 3, we
performed a time-course of stimulation of MCF7 cells with insulin
or PMA. Interestingly, the kinetics of Ser167 phosphorylation were
different after insulin and PMA stimulation. Insulin-induced
Ser167 stimulation peaked at 30 min, which correlated with acti-
vation of S6K1 measured by phosphorylation at Thr389 and phos-
phorylation of S6 at Ser240/244. In contrast, PMA-stimulated
Ser167 phosphorylation was detectable as early as 10 min, preced-
ing full activation of S6K1 and phosphorylation of S6 at Ser240/
244. Notably, phosphorylation of S6 at Ser235/236, residues that
are also phosphorylated by RSK [6], mirrored the kinetics of
Ser167 phosphorylation, indicating that the MAPK/RSK pathway
contributes to phosphorylation of Ser167 during the early phase
of stimulation with PMA.
3.5. Differential kinetics of S6K1 and RSK activation lead to biphasic
pattern of ERa Ser167 phosphorylation
In order to further delineate the contribution of S6K1 and RSK to
Ser167 phosphorylation, we compared the kinetics of PMA-stimu-
lated phosphorylation in the presence of rapamycin and/or U0126.
As shown in Fig. 4, PMA-induced Ser167 phosphorylation was ob-
served as early as after 5 min of treatment, peaking at 30 min, and
preceding full activation of S6K1. Treatment with rapamycin
greatly reduced Ser167 phosphorylation, however, the inhibition
was more pronounced at the later time points (after 15 min).
Treatment with U0126 reduced early phosphorylation of Ser167,
without having much effect on later time points. A combination
of rapamycin and U0126 abrogated Ser167 phosphorylation. This
indicated that two phases of Ser167 phosphorylation exist: an
Fig. 4. Biphasic pattern of ERa Ser167 phosphorylation by S6K1 and RSK. Cells were deprived of serum for 24 h. Cells were pre-treated with 20 ng/mL rapamycin for 30 min
and/or 10 lMU0126 for 2 h, and then stimulated with 100 ng/mL PMA, as indicated. Immunoblots were analyzed with the indicated antibodies. To accommodate the number
of lanes shown in the ﬁgure, samples were resolved using two gels, the immunoblots were developed and exposed simultaneously, and shown using two panels in the ﬁgure.
Fig. 6. mTORC1/S6K1 and MAPK/RSK pathways cooperate in promoting ERa Ser167
phosphorylation and activation. Insulin activates mTORC1 and S6K1 by signaling
via PI3K and Akt to suppress TSC and thus activate Rheb and mTORC1. Serum
signals through the PI3K pathway, as well as the Ras pathway to activate the MEK/
R.L. Yamnik, M.K. Holz / FEBS Letters 584 (2010) 124–128 127early phase that is RSK-mediated and U0126-sensitive, and a late
phase that is S6K1-mediated and rapamycin-sensitive.
Thus, S6K1 and RSK perform a non-redundant role with regard
to ERa Ser167 phosphorylation and are responsible for a biphasic
phosphorylation pattern. The early-activated RSK acts in a priming
role, while the late-responding S6K1 is responsible for the mainte-
nance of high-level phosphorylation. This may represent an impor-
tant mechanism by which the cells insure timely activation of ERa
using a combination of phosphorylating kinases.
3.6. Synergistic regulation of ERa transcriptional activity by S6K1 and
MAPK/RSK
Ser167 phosphorylation is important for the ability of ERa to
bind DNA and affect transcription of estrogen-response genes
[16]. Since we observed that both rapamycin and U0126 affected
Ser167 phosphorylation, we investigated the effect of a combina-
tion of these drugs on transcriptional activity mediated by ERa.
We transfected MCF7 cells with a reporter construct that contains
the ﬁreﬂy luciferase gene under the control of three estrogen-re-
sponse elements (ERE), and a control construct expressing renilla
luciferase under the control of SV40 promoter for luciferase activ-
ity normalization. As shown in Fig. 5, both rapamycin and U0126
signiﬁcantly reduced ERE-mediated transcriptional activity. Addi-
tionally, a combination of the two agents resulted in synergistic
inhibition. Thus S6K1 and MAPK pathways cooperate in regulation
of ERa activity (Fig. 6).Fig. 5. Synergistic inhibition of ERa transcriptional activity by rapamycin and
U0126. Cells were transfected with plasmids encoding for ERE-regulated ﬁreﬂy
luciferase, and control renilla luciferase. After 24 h transfection, cells were
incubated with full serum media in the presence or absence of 20 ng/mL rapamycin
and/or 10 lM U0126 for additional 24 h. ERE-regulated luciferase expression was
measured and normalized to control renilla luciferase. The data are presented as
means ± S.D. of each experiment performed in triplicate.
MAPK/RSK cascade. MAPK and RSK also inhibit TSC via PI3K/Akt-independent
phosphorylation of TSC2. PMA indirectly activates both S6K1 and RSK by signaling
via the protein kinase C (PKC) pathway. Thus, when activated, the MAPK and
mTORC1/S6K1 pathways signal to coordinately phosphorylate and activate ERa in
control of breast cancer cell proliferation.Estrogen receptor is an important clinical target is treatment of
breast cancer. However, resistance to anti-estrogen therapy often
develops. One of the mechanisms of resistance is through mito-
genic estrogen-independent activation of ERa. Ser167 is an impor-
tant clinical indicator of response to anti-estrogen therapy,
prognosis, and survival. Here we demonstrate that Ser167 phos-
phorylation is a result of cooperation between two important sig-
naling pathways in the cell, mTORC1 and MAPK. Clinically, MAPK
and mTORC1 activation status serve as predictors for endocrine
treatment responsiveness [18,19]. These ﬁndings may serve as a
basis for combating chemotherapy resistance with regard to anti-
estrogen or endocrine therapy. Rapamycin and its analogs, as well
as MEK inhibitors, are currently being tested alone and in combina-
tion in different types of cancer, such as melanoma [20] and lung
cancer [21,22]. While rapamycin shown an effect in early clinical
trials, the effectiveness of rapamycin in treatment of breast cancer
has been variable. We and others have demonstrated that breast
128 R.L. Yamnik, M.K. Holz / FEBS Letters 584 (2010) 124–128cells overexpressing S6K1, such as MCF7 cells are exquisitely sen-
sitive to rapamycin [16,23], suggesting a possible way to target a
population of patients most likely to respond to rapamycin treat-
ment. Thus, a question arises whether dual inhibition of the
mTORC1/S6K1 and MAPK/RSK, two major pathways leading to
ERa activation and stimulation of breast cancer cell proliferation,
may result in a better clinical response. The data presented here
provide rationale for combining rapamycin therapy with MEK
inhibitors in breast cancer with S6K1 overexpression.
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